Clinical review report: Tofacinitib (Xeljanz) (Pfizer Canada inc.) indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response, or intolerance to either conventional UC therapy or a tumour necrosis factor alpha inhibitor

The objective of this review was to perform a systematic review of the beneficial and harmful effects of tofacitinib citrate 5 mg and 10 mg tablets for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response, or intoler...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health March 2019, 2019
Edition:	Final (with redactions)
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK572261
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa